Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma - a phase II trial.
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Rafael Sauter Christoph Driessen |
| Publication date | December 16, 2016 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |